AstraZeneca’s Strategic Move to Wall Street
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
Chinese firms plan SGX listings within 12–18 months as trade tensions with the U.S. drive Southeast Asia expansion.